Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Core Viewpoint - Palvella Therapeutics, Inc. is set to ring the opening bell at the Nasdaq Stock Market on May 12, 2025, marking a significant milestone for the company as it aims to become a leading biopharmaceutical entity focused on rare genetic skin diseases [1][3]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for serious, rare genetic skin diseases that currently lack FDA-approved treatments [4]. - The company is led by veterans in rare disease drug development and is advancing a pipeline of product candidates based on its patented QTORIN™ platform [4]. - The lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is undergoing evaluation in Phase 3 and Phase 2 clinical trials for specific conditions [4]. Leadership and Ceremony - Wes Kaupinen, the Founder and CEO, will be joined by the management team, Board of Directors, investors, and guests during the opening bell ceremony [2]. - The event will be live-streamed from the Nasdaq MarketSite Tower and is intended to showcase Palvella's vision and achievements [3].